Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects
Open accessAbstract
BACKGROUND: ACD856 is a positive allosteric modulator of tropomyosin receptor kinase (Trk) receptors which has shown to have pro-cognitive and anti-depressant-like effects in various animal models. It is currently in clinical development for the treatment of Alzheimer's disease and other disorders where cognition is impaired and is also considered for indications such as depression or other neuropsychiatric diseases. ACD856 has a novel mechanism of action modulating the activity of the Trk-receptors, resulting in increased stimulation of the neurotrophin signaling pathways. Previous studies applying single intravenous and oral doses of ACD856 indicate that ACD856 is safe and well-tolerated by healthy volunteer subjects, and that it has suitable safety and pharmacokinetic properties for further clinical development. OBJECTIVES: To investigate the safety and tolerability of 7 days of treatment with multiple ascending oral doses of ACD856 in healthy subjects, and to characterize its pharmacokinetic (PK) properties. In addition, pharmacodynamic effects of ACD856 using quantitative electroencephalography (qEEG) as an indicator for central target engagement were assessed. DESIGN: This was a prospective, phase I, double-blind, parallel-group, placebo-controlled, randomized study of the safety, tolerability, PK and pharmacodynamics of multiple ascending oral doses of ACD856 in healthy subjects. ACD856 or placebo were administered in 3 ascending dose cohorts of 8 subjects. Within each cohort, subjects were randomized to receive either ACD856 (n=6) or placebo (n=2). SETTING: The study was conducted at a First-in-Human unit in Sweden. PARTICIPANTS: Twenty-four healthy male and female subjects. INTERVENTION: The study medication was administered as an oral solution, with ACD856 or the same contents without the active ingredient (placebo). The dose levels ranged from 10 mg to 90 mg. ACD856 was administered once daily for 7 days, targeting steady state. MEASUREMENTS: Safety and tolerability assessments included adverse events, laboratory, vital signs, 12-lead electrocardiogram (ECG), physical examination, assessment of stool frequency and questionnaires to assess symptoms of anxiety, depression, as well as suicidal ideation and behavior. In addition, cardiodynamic ECGs were extracted to evaluate cardiac safety. PK parameters were calculated based on measured concentrations of ACD856 in plasma, urine, and cerebrospinal fluid (CSF) samples. Metabolite profiling, characterization and analysis was performed based on and urine samples. qEEG was recorded for patients in the two highest dose cohorts (30 and 90 mg/day) as a pharmacodynamic assessment to explore central target engagement. RESULTS: Treatment with ACD856 was well tolerated with no serious adverse events. No treatment emergent or dose related trends were observed for any of the safety assessments. ACD856 was rapidly absorbed and reached maximum plasma exposure at 30 to 45 minutes after administration. Steady state was reached before Day 6, with an elimination half-life at steady state of approximately 20 hours. At steady state, ACD856 exhibited accumulation ratios for Cmax and AUC of approximately 1.6 and 1.9 respectively. The exposure, Cmax and AUC0-24, increased proportionally with the dose. There was no unchanged ACD856 detected in urine. The metabolic pattern in urine and plasma was similar, and in alignment with the metabolites observed in preclinical toxicology studies. The level of ACD856 measured in CSF at steady state increased with dose, indicating Central Nervous System (CNS) exposure at relevant levels for pharmacodynamic effects. ACD856 demonstrated significant dose-dependent treatment-associated changes on qEEG parameters. Specifically, increase of the relative theta power and decrease of the fast alpha and beta power was observed, leading to an acceleration of the delta+theta centroid and an increase in the theta/beta ratio. CONCLUSIONS: ACD856 was well tolerated at the tested dose levels (10-90 mg/daily for 7 days) in healthy subjects. The compound has a robust pharmacokinetic profile, with rapid absorption and dose-dependent exposure. ACD856 was shown to pass the blood-brain-barrier, reach relevant exposure in the CNS and to induce dose-dependent treatment-related changes on qEEG parameters, indicating central target engagement.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ACD856 demonstrated good safety and tolerability, as well as favorable pharmacokinetic properties, in a phase I study.
“In a phase I study (NCT05077501), the novel Trk receptor PAM ACD856 (58).557 demonstrated good safety and tolerability, as well as favorable pharmacokinetic properties, potentially benefiting neurotrophic factor signaling.558”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [558]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Geist, P. A., Dulka, B. N., Barnes, A., Totty, M. S., & Datta, S. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.05.039 · Cited by 18 · see citing works
RetractedThe PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · see citing works
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765 · see citing works
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · see citing works
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · see citing works
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,331 · see citing works
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,384 · see citing works
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · see citing works
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 1× · see citing works
“Recently, substantial progress has been made in the development of disease modification agents targeting the amyloid cascade (4, 5, 6) with the US Food and Drug Administration recently granting approvals for the antibodies aducanumab and lecanemab, as well as the expected filing of donanemab during…”
BackgroundTwo Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367 · see citing works
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · see citing works
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028 · see citing works
Alzheimer’s disease drug development pipeline: 2024
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12465 · Cited by 702 · see citing works
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691 · see citing works
Alzheimer’s disease drug development pipeline: 2022
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665 · see citing works
Antidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663 · see citing works
Isolated bipallidal lesions caused by extrapontine myelinolysis.
(2008) · Institutional Research Information System (Università degli Studi di Brescia) · doi:10.1212/01 · Cited by 573 · see citing works
Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer’s Disease
Jönhagen, M. E., Nordberg, A. K., Amberla, K., Bäckman, L., Ebendal, T., Meyerson, B. A., Olson, L., Seiger, Å., Shigeta, M., Theodorsson, E., et al. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017069 · Cited by 472 · see citing works
A controlled trial of recombinant methionyl human BDNF in ALS
The BDNF Study Group (Phase III) (1999) · Neurology · doi:10.1212/wnl.52.7.1427 · Cited by 453 · see citing works
Regulation of hippocampal synaptic plasticity by BDNF
Leal, G., Afonso, P. M., Salazar, I. L., & Duarte, C. B. (2015) · Brain Research · doi:10.1016/j.brainres.2014.10.019 · Cited by 410 · see citing works
Apfel, S. C., Schwartz, S., Adornato, B. T., Freeman, R. L., Biton, V., Rendell, M., Vinik, A. I., Giuliani, M. J., Stevens, J. C., Barbano, R. L., et al. (2000) · JAMA · doi:10.1001/jama.284.17.2215 · Cited by 366 · see citing works
Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats
Arancibia, S., Silhol, M., Mouliere, F. C., Meffre, J., Höllinger, I., Maurice, T., & Tapia‐Arancibia, L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.012 · Cited by 318 · see citing works
TRK inhibitors in TRK fusion-positive cancers
Drilon, A. E. D. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz282 · Cited by 297 · see citing works
Jiao, S.-S., Shen, L.-L., Zhu, C., Bu, X., Liu, Y.-H., Liu, C.-H., Yao, X.-Q., Zhang, L.-L., Zhou, H.-D., Walker, D. G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.186 · Cited by 269 · see citing works
Increased proNGF Levels in Subjects with Mild Cognitive Impairment and Mild Alzheimer Disease
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. L. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.6.641 · Cited by 236 · see citing works
Counts, S., & Mufson, E. J. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.4.263 · Cited by 222 · see citing works
Tricco, A. C., Soobiah, C., Berliner, S., Ho, J. M.-W., Ng, C., Ashoor, H. M., Chen, M. H., Hemmelgarn, B. R., & Straus, S. E. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130451 · Cited by 208 · see citing works
NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients
Sahenk, Z., Nagaraja, H., Mccracken, B. S., King, W. M., Freimer, M. L., Cedarbaum, J. M., & Mendell, J. R. (2005) · Neurology · doi:10.1212/01.wnl.0000171978.70849.c5 · Cited by 197 · see citing works
Jobert, M., Wilson, F. J., Ruigt, G. S. F., Brunovský, M., Prichep, L. S., & Drinkenburg, W. H. I. M. (2012) · Neuropsychobiology · doi:10.1159/000343478 · Cited by 186 · see citing works
Coulie, B., Szarka, L., Camilleri, M., Burton, D., Mckinzie, S., Stambler, N., & Cedarbaum, J. (2000) · Gastroenterology · doi:10.1053/gast.2000.8553 · Cited by 178 · see citing works
Neurotrophins Role in Depression Neurobiology: A Review of Basic and Clinical Evidence
Neto, F. L. M., Borges, G., Torres-Sánchez, S., Micó, J. A., & Berrocoso, E. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376262 · Cited by 150 · see citing works
Effect of BDNF val66met polymorphism on declarative memory and its neural substrate: A meta-analysis
Kambeitz, J. P., Bhattacharyya, S., Kambeitz‐Ilankovic, L., Valli, I., Collier, D. A., & McGuire, P. K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.002 · Cited by 140 · see citing works
The BDNF Val66Met Polymorphism Modulates Sleep Intensity: EEG Frequency- and State-Specificity
Bachmann, V., Klein, C., Bodenmann, S., Schäfer, N., Berger, W., Brugger, P., & Landolt, H. (2012) · SLEEP · doi:10.5665/sleep.1690 · Cited by 117 · see citing works
Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice
Kemppainen, S., Rantamäki, T., Jerónimo-Santos, A., Lavasseur, G., Autio, H., Karpova, N. N., Kärkkäinen, E., Stavén, S., Miranda, H. V., Outeiro, T. F., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.006 · Cited by 89 · see citing works
Anderer, P., Saletu, B., & Pascual-Marqui, R. D. (2000) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(00)00066-4 · Cited by 65 · see citing works
Self-citationBalsters, J. H., O’Connell, R. G., Martin, M. P., Galli, A., Cassidy, S. M., Kilcullen, S. M., Delmonte, S., Brennan, S., Meaney, J. F., Fagan, A. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024126 · Cited by 56 · see citing works
Neurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P. K. A. L., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48 · see citing works
Self-citationEffect of donepezil on EEG spectral analysis in Alzheimer's disease.
Balkan, S., Yaraş, N., Mihçi, E., Dora, B., Ağar, A., & Yargıçoğlu, P. (2003) · PubMed · Cited by 48 · see citing works
Wang, Q., Liu, J., Guo, Y., Dong, G., Zou, W., & Chen, Z. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198443 · Cited by 45 · see citing works
Flores, K. R., Viccaro, F., Aquilini, M., Scarpino, S., Ronchetti, F., Mancini, R., Napoli, A. D., Scozzi, D., & Rícci, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227834 · Cited by 43 · see citing works
Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P. (2021) · Cells · doi:10.3390/cells10081871 · Cited by 33 · see citing works
Self-citationTopographic pharmaco‐EEG mapping of increasing doses of buspirone and its comparison with diazepam
Barbanoj, M. J., Anderer, P., Antonijoan, R. M., Torrent-Farnell, J., Saletu, B., & Jané, F. (1994) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470090203 · Cited by 25 · see citing works
Self-citationSoltész, F., John Suckling, A., Lawrence, P., Tait, R. J., Ooi, C., Bentley, G., Dodds, C. M., Miller, S. R., Willé, D. R., Byrne, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095558 · Cited by 25 · see citing works
Roy, N., Barry, R. J., Fernandez, F., Lim, C. K., Al‐Dabbas, M. A., Karamacoska, D., Broyd, S. J., Solowij, N., Chiu, C. L., & Steiner, G. Z. (2020) · Scientific Reports · doi:10.1038/s41598-020-74780-9 · Cited by 22 · see citing works
Kim, K. M., Choi, S., Lee, J., & Kim, J. W. (2018) · Journal of Behavioral Addictions · doi:10.1556/2006.7.2018.43 · Cited by 19 · see citing works
Nilsson, B., Bylund, J., Halldin, M. M., Rother, M., Rein‐Hedin, E., Önnestam, K., & Segerdahl, M. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03645-1 · Cited by 7 · see citing works
Self-citationBarbero (2014) · doi:10.1016/j · Cited by 1 · see citing works
(2018) · Digital Commons@Becker (Washington University School of Medicine) · doi:10.1371/journal
Flagged first, then by citations
Research works printed but not linked: 4
- [16]16. Jiao SS, Shen LL, Zhu C, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease, Transl Psychiat 2016;6; e907. https://doi.org/10.1038/tp.2016.186 · DOI
- [19]19. Egan MF, Kojima M, Callicott, JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. Volume 2003;112. https://doi.org/10.1016/s00928674(03)00035-7 · DOI
- [21]21. Miranda M, Morici JF, Zanoni MB, et al. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Frontiers in Cellular Neuroscience. Published 2019; Aug 7. http://doi.org\10.3389/ fncel.2019.00363
- [29]29. Parrado-Fernández C, Nordvall G, Juric S, et al. Preclinical characterization of ACD856, a cognitive enhancer in clinical development for the treatment of cognitive dysfunction in Alzheimer's disease, demonstrates increased plasticity, neuroprotection and a possible disease modifying effect. Journal of Prevention of Alzheimer's Disease-JPAD, Volume 2022;9, Suppl. 1, S84-85. https://www.ctad-alzheimer.com/files/files/JPAD%20CTAD%20abstracts. pdf
Cited by
Sorted by citations
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works
Yuan, Y., & Zhao, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1522552 · Cited by 57 · see citing works
Targeting brain‐derived neurotrophic factor in the treatment of neurodegenerative diseases: A review
Wang, D., Lang, Z., Wei, S., Wang, W., & Zhang, H. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.43 · Cited by 24 · see citing works
Parrado‐Fernández, C., Juric, S., Backlund, M., Dahlström, M., Madjid, N., Lidell, V., Rasti, A., Sandin, J., Nordvall, G., & Forsell, P. K. A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311159 · Cited by 19 · see citing works
Self-citationPositive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14 · see citing works
Self-citationNilsson, B., Bylund, J., Halldin, M. M., Rother, M., Rein‐Hedin, E., Önnestam, K., & Segerdahl, M. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03645-1 · Cited by 7 · see citing works
Self-citationФедотчева, Т. А., & Shimanovsky, N. L. (2025) · Medical Sciences · doi:10.3390/medsci14010015 · Cited by 5 · see citing works
Missense variants in FRS3 affect body mass index in populations of diverse ancestries
Jonsdottir, A. B., Sveinbjörnsson, G., Þórólfsdóttir, R. B., Tamlander, M., Tragante, V., Ólafsdóttir, Þ., Rögnvaldsson, S., Sigurðsson, Á., Eggertsson, H. P., Aegisdottir, H. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57753-2 · Cited by 3 · see citing works
Gagliano, C., Avitabile, A., & Rusciano, D. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl46738
Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration
Roggiolani, E., Rosini, M., Minarini, A., & Basagni, F. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03783
- Authors
- Önnestam, K., Nilsson, B., Rother, M., Rein-Hedin, E., Bylund, J., Anderer, P., Kemethofer, M., Halldin, M. M., Sandin, J., & Segerdahl, M.
- Affiliations
- AlzeCure Pharma (Sweden) (SE)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-11
- Volume
- 10
- Issue
- 4
- Pages
- 778-789
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W4383426294
- Cited by
- 10
- References
- 40
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 1
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- positive allosteric modulators, Trk receptors, neurotrophin signaling, Alzheimer's disease, pharmacokinetics, safety and tolerability, quantitative EEG, pharmacodynamics, target engagement, first-in-human study, healthy volunteers, cardiac safety, cognitive impairment, depression
- MeSH terms
- Administration, Oral, Double-Blind Method, Electroencephalography, Female, Humans, Male, Prospective Studies, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
